Abstract: A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.

Abstract: Embodiments of the methods and compositions provided herein relate to chimeric antigen receptors (CARs) that specifically bind to B7H3. Some embodiments relate to cell-based immunotherapy targeting tumors, such as tumors comprising B7H3+ cells.

Abstract: Disclosed herein is a component for a tubing clip having a body having a first end and a second end, a first tube channel, and a first arcuate arm and a second arcuate arm spaced along the body. The first arcuate arm defines the first tube channel and has a first connecting structure and the second arcuate arm has a second connecting structure for adjustably connecting to a second component.

Abstract: Aspects herein provide a system, media, and methods for/of an application that utilizes collected telecommunication data, to accurately identify directions from a UE to a nearest coverage area. In aspects, the technology assists a user (i.e., subscriber) by navigating the user, via a UE, to a geolocation that includes some type of wireless cellular coverage, for example, through a telecommunications carrier, a roaming carrier, and/or an emergency carrier.

Abstract: Aspects herein provide a system, media, and methods for/of an application that utilizes collected telecommunication data, to accurately identify directions from a UE to a nearest coverage area. In aspects, the technology assists a user (i.e., subscriber) by navigating the user, via a UE, to a geolocation that includes some type of wireless cellular coverage, for example, through a telecommunications carrier, a roaming carrier, and/or an emergency carrier.

Abstract: The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells wherein the CAR T cells comprise a CAR and the CAR comprises an E2 anti-fluorescein antibody fragment, and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.

Abstract: The embodiments set forth a technique for coordinating notifications across computing devices placed onto a wireless charging apparatus. According to some embodiments, the technique can involve the wireless charging apparatus (1) receiving, from a first computing device, first information that includes (i) a first unique identifier (ID) associated with the first computing device, and (ii) one or more unique IDs that are each associated with a respective auxiliary computing device known to the first computing device. Subsequently, the wireless charging apparatus can receive, from a second computing device, second information that at least includes a second unique ID associated with the second computing device. Finally, the wireless charging apparatus can, in response to determining that the second unique ID is included in the one or more unique IDs, and cause both the first and second computing devices to display respective notifications in a coordinated manner.

Abstract: Aspects of the invention described herein include methods of treating, inhibiting, ameliorating and/or eliminating a virus or cancer cells in a subject utilizing genetically engineered human T-cells having receptors for a molecule presented by the virus or the cancer cells, wherein the genetically engineered T cells are isolated utilizing a two-stage MTX selection that employs increasing concentrations of MTX.

Abstract: Activity-inducible fusion proteins including a transcription factor and a heat-shock protein 90 (hsp90) binding domain are described. The activity of the transcription factor is regulated utilizing a drug molecule that binds the hsp90 binding domain. In the absence of the drug molecule, the transcription factor is in an inactive state but can be activated in the presence of the drug molecule. The activity-inducible transcription factors can be used to alter the activation state of immune cells, and optionally can be co-expressed with a chimeric antigen receptor (CAR).

Abstract: The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.

Abstract: A method for transitioning a roaming user equipment (UE) to its home network. The method includes detecting by a roaming transition manager the presence of the UE in an idle state, and detecting by the roaming transition manager that a signal strength of a roaming connection established between the UE and a visited network of the user is less than a predefined threshold. The method additionally includes triggering by the roaming transition manager, the UE to search for an access node of a home network of the user within range of the UE. The method further includes terminating the roaming connection in response to locating an access node of the home network within range of the UE, and establishing a home connection between the UE and the home network in response to locating the access node of the home network within range of the UE.

Abstract: A CD20-OR-CD19 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD20-OR-CD19 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD20-OR-CD19 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.

Abstract: A CD20-OR-CD19 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD20-OR-CD19 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD20-OR-CD19 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.

Abstract: A vehicle cover including a flexible enclosure attached to a base. The vehicle can be driven onto the base, and the enclosure can then be draped over the vehicle, and fastened to the base, so that the vehicle cover completely encapsulates the vehicle in a waterproof and hermetically sealed manner.

Abstract: Some embodiments of the methods and compositions provided herein relate to chimeric antigen receptors (CARs) that specifically bind to human extracellular domains of the IL-13 alpha 2 (IL13Ra2) receptor, cells containing such CARs, and methods of cell-based immunotherapy targeting cancer cells, such as cells of solid tumors.

Abstract: The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor under the control of an inducible promoter. In some alternatives the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, a polynucleotide comprising a spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain under the control of a drug inducible promoter. Controlling the expression of the chimeric receptor provides for the ability to turn expression on and off depending on the status of the patient.

Abstract: Various implementations described herein relate to oligonucleotides that specifically bind ?4?1. According to some implementations, oligonucleotides are conjugated to a support, a tag, a linker, or a drug. Compositions described herein can be used for diagnosis or treatment of various diseases, such as T cell-mediated autoimmune diseases. An example method includes exposing a solution of cells to the oligonucleotides and isolating cells that express ?4?1 from the solution of cells, wherein the cells that express ?4?1 are bound to the oligonucleotides. Example methods and compositions described herein can be used for cell selection, diagnostic, therapeutic, or research purposes.

Abstract: Embodiments disclosed herein include communication dies for mm-wave and/or sub-terahertz wavelength communications. In an embodiment, a communications die comprises a substrate with a first face and a second face. In an embodiment, edge surfaces connect the first face to the second face. In an embodiment, a circuitry element is on the first face, and an antenna on at least one of the edge surfaces.

Abstract: Some embodiments provided herein relate to methods and compositions for making genetically modified T cells. In some such embodiments, CD4+ and CD8+ T cells are cultured in a single serum-free volume. In some embodiments, co-cultured CD4+ and CD8+ T cells can be transduced with a lentiviral vector, and a population of transduced T cells can be harvested within a shorter period of time than other conventional methods.

Abstract: Provided are methods for preventing or ameliorating toxicity caused by or due to a therapy, such as an immunotherapy or a cell therapy, by pre-emptive or early administration toxicity-targeting agent(s). In some embodiments, the therapy is a cell therapy in which the cells generally express recombinant receptors such as chimeric receptors, e.g., chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the methods, including the timing of the administration of the agents or treatments for toxicity, provide various advantages, such as lower toxicity while maintaining persistence and efficacy of the administered cells.